HANGZHOU, China, July 26 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. , one of mainland China’s leading pharmaceutical companies, announced today that the Company has issued a Corporate Fact Sheet for a recently initiated global marketing and media communications campaign. The fact sheet along with additional information about Aida Pharmaceuticals is available at: http://www.equityperformancegroup.com/clients_aida.php.
The Corporate Fact Sheet is a comprehensive corporate summary of Aida Pharmaceuticals, the Company’s business model, its pharmaceutical drug pipeline, emerging catalysts and the Chinese pharmaceuticals market. The report also includes information on the Chinese economy and Aida’s market opportunity along with the Company’s prospects for future growth. Aida Pharmaceuticals intends to use the collateral for outreach to American media and for financial marketing efforts. The following is an excerpt:
“Due to the Company’s established market share and the profitability of Etimicin, Aida’s balance sheet has remained strong while incubating its pipeline drugs, all in various stages of development. Aida expects an average revenue growth rate of over 30% through the next five years, based on the future commercialization of its product pipeline, growth of current sales and strategic acquisitions.”
To view the complete Corporate Fact Sheet and for full disclosure terms, please visit http://www.equityperformancegroup.com/aida_CorpFS.pdf.
About Aida Pharmaceuticals:
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company’s mission is to discover, develop and market meaningful new therapies that improve human health. Aida, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China, Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category “A” drug by the State Food and Drug Administration of China.
Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Bethany Tomich (617) 723-1465 Bethany@equityperfgp.comhttp://www.EquityPerformanceGroup.com
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
This press release includes certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management’s current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations are detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov.
Aida Pharmaceuticals, Inc.
CONTACT: Bethany Tomich of Equity Performance Group for AidaPharmaceuticals (Investor Relations), +1-617-723-1465,Bethany@equityperfgp.com
